ClinVar Miner

Submissions for variant NM_002878.4(RAD51D):c.345G>A (p.Gln115=)

dbSNP: rs1555568469
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color Diagnostics, LLC DBA Color Health RCV000583256 SCV000691330 uncertain significance Hereditary cancer-predisposing syndrome 2019-04-03 criteria provided, single submitter clinical testing
Ambry Genetics RCV000583256 SCV001181826 uncertain significance Hereditary cancer-predisposing syndrome 2021-06-10 criteria provided, single submitter clinical testing The c.345G>A variant (also known as p.Q115Q), located in coding exon 4 of the RAD51D gene, results from a G to A substitution at nucleotide position 345. This nucleotide substitution does not change the amino acid at codon 115. However, this change occurs in the last base pair of coding exon 4, which makes it likely to have some effect on normal mRNA splicing. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Internal RNA studies as well as in the literature have shown that exons 3 through 5 are excluded in several naturally occurring RAD51D transcripts (Davy G et al. Eur. J. Hum. Genet., 2017 10;25:1147-1154; Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
German Consortium for Hereditary Breast and Ovarian Cancer, University Hospital Cologne RCV003483683 SCV004228286 uncertain significance Hereditary breast ovarian cancer syndrome 2024-01-08 criteria provided, single submitter curation Own splice analysis not quantitative. Quantitative splice analysis and segregation data needed. According to the ACMG standard criteria we chose these criteria: PS3 (strong pathogenic): Enhanced skipping of exon 4 in RNA-analysis. Quantification not possible., PM2 (supporting pathogenic): not in gnomAD, PP3 (supporting pathogenic): PP3 (spliceAI: RAD51D: 0.9)
Myriad Genetics, Inc. RCV004024644 SCV004933564 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 4 2024-01-04 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. mRNA analysis has demonstrated abnormal mRNA splicing occurs [Myriad internal data].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.